This article is taken from the monthly Sciences et Avenir n°941-942, dated July-August 2025.
“2040 Target: 80 % of cured patients, announced in January the Gustave-Roussy Institute in Villejuif, a benchmark in cancer care. For its general director Fabrice Barlesi, "The impact of immunotherapies will be major", and will concern almost "all the sick “.
English 
French